Pre-Made Lorukafusp Alfa biosimilar, Fusion Protein: Recombinant therapeutic protein targeting ganglioside GD2 fused with human IL2 (interleukin 2, IL-2) for drug discovery and mechanism of action (MOA) research

Pre-Made Lorukafusp Alfa biosimilar, Fusion Protein: Recombinant therapeutic protein targeting ganglioside GD2 fused with human IL2 (interleukin 2, IL-2) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Lorukafusp Alfa is a fusion protein comprised of a monoclonal antibody targeting the GD2 disialoganglioside linked to interleukin-2, which may inhibit growth and induce an immune response against GD2-expressing tumors

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-898-1mg	1mg	3090
GMP-Bios-INN-898-10mg	10mg	Inquiry
GMP-Bios-INN-898-100mg	100mg	Inquiry
GMP-Bios-INN-898-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Lorukafusp Alfa biosimilar, Fusion Protein: Recombinant therapeutic protein targeting ganglioside GD2 fused with human IL2 (interleukin 2, IL-2)
INN Name	Lorukafusp Alfa
Target	ganglioside GD2
Format	Fusion Protein
Derivation	Chimeric
Species Reactivity	human
CH1 Isotype	IgG1 - kappa
VD LC	IgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	APEIRON Biologics AG (Vienna Austria)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0